SABS

SEC source: 0001209191-22-060442 · doc4.xml · nonDerivative · entry 1

Spragens Jeffrey G · CIK 0001410620 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 394,989

F1 · date: On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. Jeffrey Spragens in connection with a private placement conducted by the Registrant, pursuant to which Mr. Spragens purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

F1 · price: On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. Jeffrey Spragens in connection with a private placement conducted by the Registrant, pursuant to which Mr. Spragens purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

SEC source: 0001209191-22-060440 · doc4.xml · derivative · entry 2

Link David Charles · CIK 0001889464 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,493

Underlying: Common Stock · 41,493 shares

Expires 2027-12-07

F1 · price: On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. David Link in connection with a private placement conducted by the Registrant, pursuant to which Mr. Link purchased (i) an aggregate of 41,493 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 41,493 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

SEC source: 0001209191-22-060440 · doc4.xml · nonDerivative · entry 1

Link David Charles · CIK 0001889464 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,313

F1 · date: On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. David Link in connection with a private placement conducted by the Registrant, pursuant to which Mr. Link purchased (i) an aggregate of 41,493 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 41,493 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

F1 · price: On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. David Link in connection with a private placement conducted by the Registrant, pursuant to which Mr. Link purchased (i) an aggregate of 41,493 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 41,493 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

SEC source: 0001209191-22-049950 · doc4.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,993,090

F1 · balance_after: Does not include: (i) 25,000 shares of common stock held by Christensen Investments, LLC, (ii) 2,909,022 shares of common stock held by the reporting persons spouse, Dr. Edward Hamilton, and (iii) 91,261 shares of common stock which the reporting person co-owns with Dr. Hamilton, all of which the reporting person may be deemed to beneficially own. The reporting person disclaims any beneficial ownership of these shares of common stock other than to the extent of any pecuniary interests the reporting person may have therein.

SEC source: 0001209191-22-050106 · doc4.xml · derivative · entry 1

Reich Samuel J · CIK 0001394645 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 525,000

Underlying: Common Stock · 525,000 shares

Expires 2032-09-13

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0001209191-22-050105 · doc4.xml · derivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-09-13

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0001209191-22-050094 · doc4.xml · derivative · entry 1

Giberson Scott · CIK 0001937585 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-09-13

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a three-year period, vesting 1/36 monthly beginning with the month following the Reporting Person's commencement of service as a director (July 6, 2022). This represents the initial grant to the Reporting Person as a member of the Board of Directors.

SEC source: 0001209191-22-050093 · doc4.xml · derivative · entry 1

Kropotova Alexandra · CIK 0001825323 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,325

Underlying: Common Stock · 18,325 shares

Expires 2032-09-13

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0001209191-22-050082 · doc4.xml · derivative · entry 1

Bausch Christoph Lawrence · CIK 0001889981 · CHIEF OPERATING OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 274,875

Underlying: Common Stock · 274,875 shares

Expires 2032-09-13

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0001209191-22-050081 · doc4.xml · derivative · entry 1

Beyer Russell P · CIK 0001889754 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 274,875

Underlying: Common Stock · 274,875 shares

Expires 2032-09-13

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0001209191-22-049168 · doc4.xml · nonDerivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,230,564

SEC source: 0001437749-23-003040 · rdgdoc.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse.

Disclosed balance after: 3,083,270

F1 · price: Represents a bona fide gift of common stock for no consideration.

SEC source: 0001209191-22-034919 · doc4.xml · nonDerivative · entry 1

Kropotova Alexandra · CIK 0001825323 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

F1 · security: Restricted Stock Unit ("RSU") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on June 6, 2023, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date.

F1 · shares: Restricted Stock Unit ("RSU") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on June 6, 2023, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-22-031401 · doc4.xml · nonDerivative · entry 1

Spragens Jeffrey G · CIK 0001410620 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 312,002

F1 · kind: The Reporting Person received 207,001 shares as part of a pro-rata distribution by Big Cypress Holdings LLC, which the Reporting Person is a limited partner of, of which shares he previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis.

F1 · price: The Reporting Person received 207,001 shares as part of a pro-rata distribution by Big Cypress Holdings LLC, which the Reporting Person is a limited partner of, of which shares he previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis.

SEC source: 0001209191-22-031398 · doc4.xml · nonDerivative · entry 2

Reich Samuel J · CIK 0001394645 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,001

F2 · kind: The Reporting Person received 207,001 shares as part of the distribution, which the Reporting Person previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis.

F2 · price: The Reporting Person received 207,001 shares as part of the distribution, which the Reporting Person previously had an indirect pecuniary interest. Therefore, the transaction, which only changes the form of the Reporting Person's ownership without increasing or decreasing his pecuniary interest, is exempt from the reporting requirements of Section 16 pursuant to Rule 16a-13. Notwithstanding, the Reporting Person is reporting the acquisition on a voluntary basis.

SEC source: 0001209191-22-031398 · doc4.xml · nonDerivative · entry 1

Reich Samuel J · CIK 0001394645 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Indirect · Via Big Cypress Holdings LLC

Disclosed balance after: 547,698

F1 · kind: Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a managing member of Big Cypress Holdings LLC, and as part of the distribution will receive 207,001 shares of the issuer, which the Reporting Person previously had an indirect pecuniary interest.

F1 · price: Pro rata distribution by Big Cypress Holdings LLC to its members for which no consideration is being paid in connection with such distribution. The Reporting Person is a managing member of Big Cypress Holdings LLC, and as part of the distribution will receive 207,001 shares of the issuer, which the Reporting Person previously had an indirect pecuniary interest.

SEC source: 0000899243-22-011667 · doc4.xml · derivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,218

Underlying: Common Stock · 21,218 shares

Expires 2033-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0000899243-22-011666 · doc4.xml · derivative · entry 1

Beyer Russell P · CIK 0001889754 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2032-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0000899243-22-011665 · doc4.xml · derivative · entry 1

Luke Thomas Charles · CIK 0001889689 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,519

Underlying: Common Stock · 20,519 shares

Expires 2032-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0000899243-22-011664 · doc4.xml · derivative · entry 1

Finnegan Frederick · CIK 0001291694 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,453

Underlying: Common Stock · 23,453 shares

Expires 2032-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0000899243-22-011663 · doc4.xml · derivative · entry 1

Reich Samuel J · CIK 0001394645 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2032-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0000899243-22-011662 · doc4.xml · derivative · entry 1

Ullerich Melissa Vera · CIK 0001889813 · Chief Communications Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,405

Underlying: Common Stock · 16,405 shares

Expires 2032-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0000899243-22-011661 · doc4.xml · derivative · entry 1

Pommer Jerry Lynn · CIK 0001889416 · Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,172

Underlying: Common Stock · 15,172 shares

Expires 2032-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0000899243-22-011660 · doc4.xml · derivative · entry 1

Bausch Christoph Lawrence · CIK 0001889981 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,972

Underlying: Common Stock · 24,972 shares

Expires 2032-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0000899243-22-011659 · doc4.xml · derivative · entry 1

Erickson Bruce Kipp · CIK 0001889685 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,196

Underlying: Common Stock · 18,196 shares

Expires 2032-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0001493152-21-029370 · ownership.xml · derivative · entry 1

Reich Samuel J · CIK 0001394645 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2031-11-17

F1 · shares: Represents options to purchase shares of common stock granted to the Reporting Person pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a three-year period, vesting 1/3 on the one-year anniversary of the date of grant, and the remaining 2/3 vesting pro rata on a monthly basis in 24 equal installments thereafter.

SEC source: 0001493152-21-029395 · ownership.xml · derivative · entry 1

Beyer Russell P · CIK 0001889754 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2031-11-17

F1 · shares: Represents options to purchase shares of common stock granted to the Reporting Person pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0001493152-21-028917 · ownership.xml · nonDerivative · entry 4

Beyer Russell P · CIK 0001889754 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 0

F2 · kind: The sale of Issuer common stock by the reporting person's spouse reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 278 shares, with the purchase of 278 shares of Issuer's common stock as also reported herein. The reporting person has paid to Issuer, upon settlement of the sale, $15.48, representing the full amount of the profit realized in connection with the short-swing transaction.

SEC source: 0001493152-21-028917 · ownership.xml · nonDerivative · entry 3

Beyer Russell P · CIK 0001889754 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 278

SEC source: 0001493152-21-026394 · ownership.xml · derivative · entry 1

Carillo Carlos N · CIK 0001889694 · SVP Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,681

Underlying: Common Stock · 17,681 shares

Expires 2031-05-27

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · price: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, May 24, 2021, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · derivative.exercise_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, May 24, 2021, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

SEC source: 0001493152-21-026393 · ownership.xml · derivative · entry 1

Erickson Bruce Kipp · CIK 0001889685 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,642

Underlying: Common Stock · 232,642 shares

Expires 2031-05-27

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · price: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, March 1, 2021, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · derivative.exercise_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, March 1, 2021, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

SEC source: 0001493152-21-026392 · ownership.xml · derivative · entry 5

Wu Hua · CIK 0001889408 · SVP Research & Product Dev.

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 4,653

Underlying: Common Stock · 4,653 shares

Expires 2028-01-01

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · price: The option is fully vested.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026392 · ownership.xml · derivative · entry 4

Wu Hua · CIK 0001889408 · SVP Research & Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,191

Underlying: Common Stock · 32,191 shares

Expires not disclosed

F3 · derivative.exercise_price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F4 · derivative.exercise_price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period

F3 · price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F4 · price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period

F3 · derivative.exercise_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F4 · derivative.exercise_date: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period

F3 · derivative.expiration_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

SEC source: 0001493152-21-026392 · ownership.xml · derivative · entry 3

Wu Hua · CIK 0001889408 · SVP Research & Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,979

Underlying: Common Stock · 6,979 shares

Expires 2030-04-27

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · price: The option is fully vested.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026392 · ownership.xml · derivative · entry 2

Wu Hua · CIK 0001889408 · SVP Research & Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,540

Underlying: Common Stock · 14,540 shares

Expires 2024-12-12

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · price: The option is fully vested.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026392 · ownership.xml · derivative · entry 1

Wu Hua · CIK 0001889408 · SVP Research & Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,161

Underlying: Common Stock · 58,161 shares

Expires 2024-08-05

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · price: The option is fully vested.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026391 · ownership.xml · derivative · entry 2

Polvino William James · CIK 0001889459 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,748

Underlying: Common Stock · 11,748 shares

Expires not disclosed

F3 · derivative.exercise_price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F4 · derivative.exercise_price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F3 · price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F4 · price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F3 · derivative.exercise_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F4 · derivative.exercise_date: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F3 · derivative.expiration_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

SEC source: 0001493152-21-026391 · ownership.xml · derivative · entry 1

Polvino William James · CIK 0001889459 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,585

Underlying: Common Stock · 139,585 shares

Expires 2031-01-01

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · price: The option is fully vested.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

F2 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026390 · ownership.xml · derivative · entry 5

Finnegan Frederick · CIK 0001291694 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,152

Underlying: Common Stock · 60,152 shares

Expires not disclosed

F6 · derivative.exercise_price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F6 · price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F6 · derivative.exercise_date: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F5 · derivative.expiration_date: The option is fully vested.

SEC source: 0001493152-21-026390 · ownership.xml · derivative · entry 4

Finnegan Frederick · CIK 0001291694 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,627

Underlying: Common Stock · 125,627 shares

Expires 2028-09-01

F4 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F5 · price: The option is fully vested.

F4 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F5 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026390 · ownership.xml · derivative · entry 3

Finnegan Frederick · CIK 0001291694 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,264

Underlying: Common Stock · 23,264 shares

Expires 2028-09-01

F4 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F5 · price: The option is fully vested.

F4 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F5 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026390 · ownership.xml · derivative · entry 2

Finnegan Frederick · CIK 0001291694 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,593

Underlying: Common Stock · 15,593 shares

Expires not disclosed

F2 · derivative.exercise_price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F3 · derivative.exercise_price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F2 · price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F3 · price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F2 · derivative.exercise_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F3 · derivative.exercise_date: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F2 · derivative.expiration_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

SEC source: 0001493152-21-026390 · ownership.xml · nonDerivative · entry 1

Finnegan Frederick · CIK 0001291694 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,596

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each share of Old SAB Biotherapeutics issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

SEC source: 0001493152-21-026389 · ownership.xml · derivative · entry 21

Hamilton Edward D. · CIK 0001889477 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 47,777

Underlying: Common Stock · 47,777 shares

Expires not disclosed

F7 · derivative.exercise_price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F7 · price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F7 · derivative.exercise_date: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F6 · derivative.expiration_date: The option is fully vested.

SEC source: 0001493152-21-026389 · ownership.xml · derivative · entry 20

Hamilton Edward D. · CIK 0001889477 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 69,793

Underlying: Common Stock · 69,793 shares

Expires 2031-01-01

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F9 · price: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2020, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F9 · derivative.exercise_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2020, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

SEC source: 0001493152-21-026389 · ownership.xml · derivative · entry 19

Hamilton Edward D. · CIK 0001889477 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 23,264

Underlying: Common Stock · 23,264 shares

Expires 2029-05-03

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F8 · price: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, May 3, 2019, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F8 · derivative.exercise_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, May 3, 2019, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

SEC source: 0001493152-21-026389 · ownership.xml · derivative · entry 18

Hamilton Edward D. · CIK 0001889477 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 11,632

Underlying: Common Stock · 11,632 shares

Expires 2028-07-01

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · price: The option is fully vested.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026389 · ownership.xml · derivative · entry 17

Hamilton Edward D. · CIK 0001889477 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 11,632

Underlying: Common Stock · 11,632 shares

Expires 2025-12-15

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · price: The option is fully vested.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026389 · ownership.xml · derivative · entry 16

Hamilton Edward D. · CIK 0001889477 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 34,896

Underlying: Common Stock · 34,896 shares

Expires 2025-07-01

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · price: The option is fully vested.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026389 · ownership.xml · derivative · entry 15

Hamilton Edward D. · CIK 0001889477 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 11,632

Underlying: Common Stock · 11,632 shares

Expires 2024-12-12

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · price: The option is fully vested.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · derivative.exercise_date: The option is fully vested.